Citi analyst Joanne Wuensch lowered the firm’s price target on DexCom (DXCM) to $75 from $85 and keeps a Buy rating on the shares post the Q3 report The firm believes management talking down 2026 expectations will pressure the shares in the near term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target lowered to $93 from $98 at Wells Fargo
- DexCom price target lowered to $99 from $106 at Canaccord
- Dexcom’s Stock Weakness Presents a Buy Opportunity Amid Strong Growth Prospects and Strategic Guidance
- Dexcom Reports Strong Q3 2025 Growth and Raises Guidance
- Dexcom’s Strong Q3 Performance and Future Growth Potential Justify Buy Rating